GNFTGenfit S.A.

Nasdaq genfit.com


$ 3.67 $ -0.12 (-3.05 %)    

Tuesday, 25-Jun-2024 15:09:17 EDT
QQQ $ 479.35 $ 5.42 (1.14 %)
DIA $ 391.06 $ -2.96 (-0.75 %)
SPY $ 544.78 $ 2.09 (0.39 %)
TLT $ 94.49 $ 0.16 (0.17 %)
GLD $ 214.55 $ -1.07 (-0.5 %)
$ 3.81
$ 3.67
$ 3.77 x 312
$ 0.00 x 0
$ 3.67 - $ 3.67
$ 2.89 - $ 6.05
13,754
na
189.87M
$ 0.66
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 fda-fast-tracks-ipsen-and-genfits-new-liver-disease-treatment-iqirvo

The U.S. FDA has granted accelerated approval for Iqirvo, a novel drug from Ipsen SA and Genfit SA, designed for treating prima...

 hc-wainwright--co-maintains-buy-on-genfit-raises-price-target-to-13

HC Wainwright & Co. analyst Ed Arce maintains Genfit (NASDAQ:GNFT) with a Buy and raises the price target from $11 to $13.

Core News & Articles

GENFIT is eligible to receive a €48.7 million milestone payment from Ipsen upon the first commercial sale of Iqirvo in the U.S....

Core News & Articles

Iqirvo is a first-in-class oral, once-daily peroxisome proliferator-activated receptor (PPAR) agonist. Iqirvo was in-licensed f...

 hc-wainwright--co-reiterates-buy-on-genfit-maintains-11-price-target

HC Wainwright & Co. analyst Ed Arce reiterates Genfit (NASDAQ:GNFT) with a Buy and maintains $11 price target.

 hc-wainwright--co-reiterates-buy-on-genfit-maintains-11-price-target

HC Wainwright & Co. analyst Ed Arce reiterates Genfit (NASDAQ:GNFT) with a Buy and maintains $11 price target.

 hc-wainwright--co-reiterates-buy-on-genfit-maintains-11-price-target

HC Wainwright & Co. analyst Ed Arce reiterates Genfit (NASDAQ:GNFT) with a Buy and maintains $11 price target.

 genfit-fy23-eps-062-down-from-049-yoy-sales-4109m-up-from-2712m-yoy

Genfit (NASDAQ:GNFT) reported quarterly losses of $(0.62) per share. This is a 26.53 percent decrease over losses of $(0.49) pe...

 earnings-scheduled-for-april-4-2024

Companies Reporting Before The Bell • Conagra Brands (NYSE:CAG) is likely to report quarterly earnings at $0.65 per share on r...

 hc-wainwright--co-reiterates-buy-on-genfit-maintains-11-price-target

HC Wainwright & Co. analyst Ed Arce reiterates Genfit (NASDAQ:GNFT) with a Buy and maintains $11 price target.

Core News & Articles

Ipsen ((Euronext: IPN, OTC:IPSEY) and GENFIT (Nasdaq and Euronext: GNFT) today announced that the U.S. Food and Drug Administra...

 genfit-announces-publication-in-the-journal-of-hepatology-on-the-accurate-performance-of-nis2-as-a-screening-tool-for-the-enrollment-of-patients-in-mash-clinical-trials

The paper published in Journal of Hepatology demonstrates that NIS2+™ technology could significantly reduce liver biopsy failur...